• Therapeutics >

Antibody-Based Cancer Biomarkers And Therapeutic Agents

Background:
The National Cancer Institute's Mammary Biology and Tumorigenesis Laboratory is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize isoform-specifc antibodies to the human prolactin receptor.

Technology:
Prolactin is a key hormone in normal breast development and plays a role in the growth and development of other major organs such as the prostate. The biologic function of prolactin is mediated by specific receptors on the cell surface, with breast cancer cells containing more receptors than normal tissue. The prolactin receptor, a member of the large class-1 cytokine receptor superfamily, has three major isoforms that are cell associated. The specific isoform concentration and distribution determines biological activity and may determine susceptibility to antiprolactin drugs.

This technology describes several antibodies, both polyclonal and monoclonal, to the prolactin receptor. These include antibodies to the three major isoforms: the long isoform (LF), two short isoforms (SF1a and SF1b), and the secreted form, prolactin receptor 7-11.  These antibodies can be used for the diagnosis of prolactin sensitive tumors as well as for the development of targeted cancer therapeutics.  Furthermore, the presence of the secreted prolactin receptor 7-11 may provide a blood test for prolactin responsive tumors.

Further R&D Needed:

• Screening of breast and prostate cancers by immunohistochemistry for receptor isoforms
• Screening of serum from breast cancer patients 
• Examine isoform profiles in normal, high-risk and cancer patients

• Diagnostic tool for the detection of prolactin sensitive tumors
• Development of conjugated antibodies used in targeted therapy of cancer
• Use of antibodies as a serum diagnostic in high-throughput assays
  

This opportunity is also listed under the following categories:

• Diagnostics